Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison CVE:AGRLNASDAQ:ASNDCVE:KZDNYSE:MTR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGRLAguia ResourcesC$0.13-7.1%C$0.13C$0.08▼C$0.18C$24.14MN/A418,301 shs361,698 shsASNDAscendis Pharma A/S$148.44-1.0%$145.24$64.33▼$161.00$8.57B0.52389,823 shs243,699 shsKZDKaizen DiscoveryC$0.09-5.6%C$0.09C$0.08▼C$0.21C$5.61M1.3811,790 shs1,000 shsMTRMesa Royalty Trust$10.40-0.5%$10.19$8.85▼$29.50$19.48M0.729,291 shs4,665 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGRLAguia Resources0.00%0.00%0.00%0.00%0.00%ASNDAscendis Pharma A/S-1.01%+2.92%-5.78%+16.55%+35.29%KZDKaizen Discovery0.00%0.00%0.00%-22.73%-32.00%MTRMesa Royalty Trust-0.81%+7.61%+16.67%-21.31%-36.27%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGRLAguia ResourcesN/AN/AN/AN/AN/AN/AN/AN/AASNDAscendis Pharma A/S0.8715 of 5 stars2.42.00.00.02.21.70.6KZDKaizen DiscoveryN/AN/AN/AN/AN/AN/AN/AN/AMTRMesa Royalty TrustN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGRLAguia ResourcesN/AN/AN/AN/AASNDAscendis Pharma A/S2.70Moderate Buy$174.1417.32% UpsideKZDKaizen DiscoveryN/AN/AN/AN/AMTRMesa Royalty TrustN/AN/AN/AN/ACurrent Analyst RatingsLatest ASND, MTR, MRP, AGRL, and KZD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024ASNDAscendis Pharma A/SWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$196.00 ➝ $260.002/8/2024ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$146.00 ➝ $182.002/8/2024ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$207.00 ➝ $225.002/6/2024ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$152.00 ➝ $173.001/8/2024ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$202.00 ➝ $207.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGRLAguia ResourcesC$-8.39K-2,877.23C$0.01 per share14.00C$0.19 per share0.69ASNDAscendis Pharma A/S$288.08M29.74N/AN/A($2.73) per share-54.37KZDKaizen DiscoveryN/AN/AC$0.01 per share6.04C$0.04 per shareN/AMTRMesa Royalty Trust$4.12M4.69$1.97 per share5.29$1.44 per share7.22Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGRLAguia ResourcesN/A-C$0.01N/A∞N/AN/AN/AN/AN/AASNDAscendis Pharma A/S-$521.07M-$9.25N/AN/AN/A-180.61%-16,574.15%-55.10%4/25/2024 (Estimated)KZDKaizen Discovery-C$2.23M-C$0.03N/A∞N/AN/A-67.62%-47.47%N/AMTRMesa Royalty Trust$3.68MN/A0.00∞N/A88.93%129.71%98.31%4/2/2024 (Estimated)Latest ASND, MTR, MRP, AGRL, and KZD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/7/2024Q4 2023ASNDAscendis Pharma A/S-$2.15-$1.66+$0.49-$1.66$97.02 million$148.62 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGRLAguia ResourcesN/AN/AN/AN/AN/AASNDAscendis Pharma A/SN/AN/AN/AN/AN/AKZDKaizen DiscoveryN/AN/AN/AN/AN/AMTRMesa Royalty Trust$0.100.96%+72.04%N/AN/ALatest ASND, MTR, MRP, AGRL, and KZD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/19/2024MTRMesa Royalty Trustmonthly$0.025216.9%3/27/20243/29/20244/30/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGRLAguia ResourcesN/A1.611.48ASNDAscendis Pharma A/S7.393.562.50KZDKaizen Discovery66.280.351.96MTRMesa Royalty TrustN/A7.237.23OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGRLAguia ResourcesN/AASNDAscendis Pharma A/SN/AKZDKaizen Discovery1.21%MTRMesa Royalty Trust12.73%Insider OwnershipCompanyInsider OwnershipAGRLAguia ResourcesN/AASNDAscendis Pharma A/S40.00%KZDKaizen Discovery82.72%MTRMesa Royalty TrustN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGRLAguia ResourcesN/A185.67 millionN/ANot OptionableASNDAscendis Pharma A/S87957.71 million34.62 millionOptionableKZDKaizen DiscoveryN/A65.94 millionN/ANot OptionableMTRMesa Royalty TrustN/A1.86 millionN/ANot OptionableASND, MTR, MRP, AGRL, and KZD HeadlinesSourceHeadlineMesa Royalty Trust Announces Trust Income for March 2024businesswire.com - March 19 at 4:15 PMMesa Royalty Stock (NYSE:MTR), Analyst Ratings, Price Targets, Predictionsbenzinga.com - February 22 at 10:28 AMMesa Royalty Trust Announces Trust Income for February 2024finance.yahoo.com - February 16 at 5:48 PMMesa Royalty Trust Announces Trust Income for February 2024businesswire.com - February 16 at 4:58 PMMesa Royalty Trust (MTR)finance.yahoo.com - February 9 at 10:17 AMMesa Royalty Trust Announces Trust Income for January 2024finance.yahoo.com - January 18 at 7:00 PMMesa Royalty Trust declares $0.0308 dividendmsn.com - December 19 at 6:33 PMMesa Royalty Trust Announces Trust Income for December 2023finance.yahoo.com - December 19 at 6:33 PMMesa Royalty Trust declares $0.0674 dividendmsn.com - November 21 at 12:05 AMMesa Royalty Trust Announces Trust Income for November 2023finance.yahoo.com - November 20 at 7:05 PMMesa Royalty Trust MTRmorningstar.com - November 9 at 1:01 PMMesa Royalty Trust declares $0.0171 dividendmsn.com - October 21 at 8:41 AMMesa Royalty Trust Announces Trust Income for October 2023finance.yahoo.com - October 19 at 5:07 PMMesa Royalty announces trust income for Septembermsn.com - September 18 at 7:44 PMMesa Royalty Trust Announces Trust Income for September 2023finance.yahoo.com - September 18 at 7:44 PMMesa Royalty Trust (MTR) Declares $0.04 Dividendmsn.com - August 30 at 3:21 AMMesa Royalty Trust Announces Trust Income for August 2023benzinga.com - August 21 at 5:43 PMMesa Royalty Trust Announces Trust Income for August 2023finance.yahoo.com - August 21 at 5:43 PMMesa Royalty Trust (MTR) Declares $0.06 Dividendmsn.com - July 28 at 7:43 AMMesa Royalty Trust Announces Trust Income for July 2023finance.yahoo.com - July 20 at 6:46 PMMesa Royalty Stock (NYSE:MTR), Insider Trading Activitybenzinga.com - July 1 at 8:26 PMMesa Royalty Trust (MTR) Declares $0.14 Dividendmsn.com - June 29 at 1:42 PMMesa Royalty Trust Announces Trust Income for June 2023finance.yahoo.com - June 20 at 7:49 PMMesa Royalty Trust goes ex-dividend on Tuesdaymsn.com - May 26 at 3:59 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAguia ResourcesCVE:AGRLAguia Resources Limited engages in the exploration and development of mineral resource projects in Brazil. Its flagship Rio Grande phosphate assets include the Três Estradas, Joca Tavares, Porteira carbonatite, and Cerro Preto deposits located in the state of Rio Grande do Sul in southern Brazil. Aguia Resources Limited was incorporated in 2007 and is based in Belo Horizonte, Brazil.Ascendis Pharma A/SNASDAQ:ASNDAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Kaizen DiscoveryCVE:KZDKaizen Discovery Inc. engages in the exploration of mineral projects in Peru and Canada. It holds interest in the Pinaya Copper-Gold Project that covers an area of 101 square kilometers and includes 10 kilometers of underexplored strike length within the Andahuaylas-Yauri Porphyry Belt in southeastern Peru. The company is headquartered in Vancouver, Canada. As of February 6, 2024, Kaizen Discovery Inc. operates as a subsidiary of Ivanhoe Electric Inc.Mesa Royalty TrustNYSE:MTRMesa Royalty Trust owns net overriding royalty interests in various oil and gas producing properties in the United States. The company has interests in properties located in the Hugoton field of Kansas; and the San Juan Basin of Northwestern New Mexico and Southwestern Colorado. Mesa Royalty Trust was founded in 1979 and is based in Houston, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.